1.ENCORE1 Study Group. (2014). Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. The Lancet, 383(9927), 1474-1482.
2. ENCORE1 Study Group. (2014). Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. The Lancet, 383(9927), 1474-1482.
3. Gallant, J. E., DeJesus, E., Arribas, J. R., Pozniak, A. L., Gazzard, B., Campo, R. E., ... & Cheng, A. K. (2006). Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. New England Journal of Medicine, 354(3), 251-260.
4.https://www.accessdata.fda.gov/drugsatfda_docs/pepfar/079071PI.pdf
5.https://medlineplus.gov/druginfo/meds/a602018.html